SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.

NEW YORK, July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS) in connection with the proposed merger of the Company with TYME Technologies, Inc. ("TYME") (NASDAQ: TYME).  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will continue to trade publicly on the Nasdaq under the ticker symbol "SYRS."  Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME's expected net cash at closing, and TYME stockholders are expected to receive approximately 0.4312 shares of Syros common stock for each share of TYME common stock. The actual number of shares to be issued in the merger and the exchange ratio will be subject to adjustment based on the amount of TYME's net cash at closing and the number of TYME shares outstanding at closing.   

Read more at prnewswire.com